Revenue: As of FY2026 Q2, the actual value is USD 81 K, missing the estimate of USD 92.45 K.

EPS: As of FY2026 Q2, the actual value is USD -0.22, beating the estimate of USD -0.2566.

EBIT: As of FY2026 Q2, the actual value is USD -26.98 M.

Financial Summary for Q2 2026 and Six Months Ended June 30, 2026

Cash and Investments

As of June 30, 2026, Perspective Therapeutics, Inc. reported approximately $237 million in cash, cash equivalents, and short-term investments, an increase from approximately $145 million as of December 31, 2025. Specifically, cash and cash equivalents were $48,488 thousand on June 30, 2026, compared to $30,629 thousand on December 31, 2025. Short-term investments increased to $188,388 thousand as of June 30, 2026, from $114,108 thousand as of December 31, 2025.

Grant Revenue

Grant revenue for the three months ended June 30, 2026, was $81 thousand, a decrease from $290 thousand for the same period in 2025. For the six months ended June 30, 2026, grant revenue was $157 thousand, down from $632 thousand in the prior year period.

Operating Expenses

Research and development expenses for the three months ended June 30, 2026, were $21,544 thousand, up from $16,620 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, these expenses totaled $42,916 thousand, compared to $30,952 thousand for the prior year period. General and administrative expenses were $7,795 thousand for the three months ended June 30, 2026, a slight increase from $7,709 thousand for the same period in 2025. For the six months ended June 30, 2026, general and administrative expenses were $14,780 thousand, compared to $15,551 thousand for the prior year period. Total operating expenses were $29,339 thousand for the three months ended June 30, 2026, versus $24,329 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, total operating expenses amounted to $57,696 thousand, an increase from $46,503 thousand in the same period of 2025.

Operating Loss

The operating loss for the three months ended June 30, 2026, was - $29,258 thousand, compared to an operating loss of - $24,039 thousand for the same period in 2025. For the six months ended June 30, 2026, the operating loss was - $57,539 thousand, compared to - $45,871 thousand for the prior year period.

Non-Operating Income (Expense)

Interest income for the three months ended June 30, 2026, was $2,347 thousand, slightly higher than $2,159 thousand for the same period in 2025. For the six months ended June 30, 2026, interest income was $4,544 thousand, similar to $4,543 thousand in the prior year period. Interest and other expense was - $71 thousand for the three months ended June 30, 2026, compared to - $119 thousand for the same period in 2025. For the six months ended June 30, 2026, this expense was - $176 thousand, down from - $247 thousand in the prior year period. Other income from a related party was $0 for both three-month periods ended June 30, 2026, and 2025. For the six months ended June 30, 2026, it was $0, compared to $1,400 thousand in the prior year period. Equity in loss of affiliate was - $1 thousand for the three months ended June 30, 2026, and $0 for the same period in 2025. For the six months ended June 30, 2026, it was - $1 thousand, consistent with - $1 thousand in the prior year period. Total non-operating income, net, was $2,275 thousand for the three months ended June 30, 2026, compared to $2,040 thousand for the same period in 2025. For the six months ended June 30, 2026, it was $4,367 thousand, compared to $5,695 thousand in the prior year period.

Net Loss

Net loss for the three months ended June 30, 2026, was - $26,786 thousand, compared to - $21,485 thousand for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $52,975 thousand, compared to - $39,662 thousand for the prior year period.

Comprehensive Loss

Comprehensive loss for the three months ended June 30, 2026, was - $26,781 thousand, compared to - $21,501 thousand for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was - $53,306 thousand, versus - $39,608 thousand for the prior year period.

Operational Highlights and Outlook

Perspective Therapeutics, Inc. is advancing VMT-α-NET towards a Phase 3 study in neuroendocrine tumors, with clinical site activation targeted around year-end 2026, subject to regulatory feedback. The company expects its current cash, cash equivalents, and short-term investments of approximately $237 million to fund planned clinical milestones and operational investments into late 2027. Manufacturing facility construction is expected to complete in Chicago in early 2027 and in Los Angeles in the second half of 2027, expanding the network to four regional sites by the end of 2027.